0105 IconOVir
BioCentury & Getty Images

Emerging Company Profile

Kite, Forty Seven vets on board for launch of oncolytic virus start-up IconOVir with $77M series A

Emerging Company Profile: With tech licensed from Salk, IconOVir is developing tumor-selective oncolytic viruses that can be administered IV

With next-generation tech licensed from the Salk Institute, IconOVir is developing tumor-selective oncolytic viruses that can be administered intravenously.

Jan 6, 2021 | 1:12 AM GMT

Developed by a

Read the full 698 word article

How to gain access

Continue reading with a
two-week free trial.